HDAC inhibitors have been found to regulate SARS-CoV-2 entry in epithelial cells by decreasing the expression of angiotensin converting enzyme 2 (ACE2) and blocking ACE2-mediated entry of the virus; consequently, they have been proposed as potential therapeutic agents for COVID-19 [16]. The gene discussed is ACE2; the disease is COVID-19.